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Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of unknown
etiology and poor prognosis; effective therapy has remained elusive and the pathogenesis enig-
matic. It has become clearer that a marked heterogeneity in disease progression exists in IPF
patients. The factors affecting the prognosis of patients with IPF are poorly understood. Poor
prognosis has been associated with older age, male gender, lower FVC, lower diffusing capacity
of the lung for carbon monoxide (DLCO), desaturation during exercise, and the extent of
fibrosis seen on imaging studies. Data from placebo-controlled trials have demonstrated that
deterioration in the conditions of IPF patients over time may not be linear. These data have
highlighted the concept and importance of acute exacerbations. Rapid respiratory decompen-
sation may be more important than previously appreciated. The development of pulmonary
arterial hypertension (PAH) in patients with pulmonary fibrosis is well recognized. The six-
minute-walk test has emerged as an important addition to prognostic evaluation, with signif-
icant oxygen desaturation identifying a subgroup of patients with a much higher mortality. It is
not yet known whether this observation denotes incipient pulmonary hypertension, itself
a malignant prognostic determinant. It appears that the six-minute-walk test might have
particular utility as a basis for prioritizing lung transplantation.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive,
fibrotic interstitial lung disease associated with a poor prog-
nosis and a median survival of 2.5 to 5 years from the time of
diagnosis.1,2 There is no effective treatment and many
patients, if eligible, are referred for lung transplantation. IPF
appears to be substantially more prevalent than previously0)2 85994580; fax: þ39 (0)2
.it (S. Harari).
0 Elsevier Ltd. All rights reservedreported; it is not clear whether these findings primarily
represent changes in clinician diagnostic thresholds or
whether there has been a real increase in disease prevalence.
However, this uncertainty should not obscure the fact that IPF
appears to be approximately as prevalent as a number of the
morecommonmalignancies, all ofwhichattract amuch larger
share of community and research resources.3 Although IPF is
likely to be more common than previously thought, with an
estimated prevalence ranging from 14 to 43 per 100,000
persons in theUnitedStates,4 it still isa raredisease.However,
rare does not mean unimportant.
The diagnosis is confirmed by the identification of usual
interstitial pneumonia (UIP) either by surgical lung biopsy.
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high-resolution CT (HRCT).1,5 While ongoing research
continues to investigate multiple hypotheses of UIP patho-
genesis, neither the natural history nor the pathogenesis of
UIP is currently well understood. The traditional view of IPF
progression holds that a slow and steady decline in respira-
tory function ultimately leads to respiratory failure and
death. Emerging evidence, however, has suggested that
multiple injuries, or hits, to the lung occur over a period of
time, and thesehits lead toacuteexacerbations that result in
periods of more rapid decline in lung function, which can
ultimately result in death.6e8 The disease course in IPF is
variable, with many patients remaining stable for long
periods of time while a significant proportion experience
exacerbations leading to respiratory failure and death.7 This
variability leads to a need for the early and accurate diag-
nosis and early referral for lung transplantation.9 The
unpredictable nature of UIP/IPF highlights the importance of
identifying factors that can help refine the prognosis for
patients at the time of initial diagnosis. Identification of
surrogate short-term measures of mortality is critical to the
management and study of patients with IPF. Several factors
have been identified that predict poor survival in patients
with IPF, including age, sex, smoking history, diffusion
capacity for carbonmonoxide (DLCO), FVC, degree of fibrosis
on HRCT of the chest, and number of fibroblastic foci on
histopathology.10e14 To date, the tools available to predict
prognosis have been imprecise and have complicated clinical
decision making regarding the use of potentially toxic ther-
apies and the timing of referral for lung transplantation.Figure 1 The frequency of fibroblastic foci in lung biopsy
from IPF patients correlates with poor prognosis.Histopathologic pattern and survival
The ATS/ERS consensus panel revised the classification
schema and emphasised the importance of an integrated
clinical, radiological and pathological approach to the
diagnosis of idiopathic interstitial pneumonia (IIP). In
addition, they concluded that the IIPs comprised a number
of clinical-pathological entities which were sufficiently
different from one another to be designated as separate
diseases.1 The published IIP classification is by no means
the final word but rather the basis for future refinement of
definition.15
The examination of SLB specimens allows identification
of histopathological subsets of IIP with different prog-
noses.1,16,17 Of these disorders, the two entities that have
provoked most discussion and debate are IPF (as currently
defined with a UIP pattern of pathology) and non-specific
interstitial pneumonia (NSIP).15 UIP is the most common
pattern of IIP, being seen in 47 to 62% of recent series
compared with 14 to 36% for NSIP.1,18e20 Previous studies
have identified the histopathologic pattern as the most
important baseline factor in determining prognosis.19,21e24
However, the disease course for individual patients with
either UIP or NSIP can vary greatly and the relationship of
NSIP to IPF remains harder to integrate.18,19,21 NSIP is often
difficult to distinguish from UIP in the setting of
IPF.18,19,21,23,25,26 Growing data suggested this is not simply
an academic or semantic argument, because UIP/IPF is
shown to carry a far worse prognosis than idiopathic NSIP in
studies where this distinction is attempted.18,19,22,23Consequently, this differentiation carried important clin-
ical implications regarding patient outcome and choice of
therapy. As the name implies, there are many ‘‘nonspe-
cific’’ features from a clinical, radiologic, and pathologic
view in NSIP. In particular, the histopathologic pattern of
NSIP could be found in a wide variety of clinical contexts,
including diseases of known cause (e.g., hypersensitivity
pneumonitis) as well as in the setting of an IIP.27 Thus, it has
been argued that when a histopathologic diagnosis of NSIP
has been made, the work of the clinician has only just
begun.28 An HRCT showing a typical pattern of UIP (in
particular, honeycomb changes) leads to a diagnosis of IPF,
even when a SLB shows histologic features of NSIP.22,29 The
histologic findings of NSIP and UIP are frequently noted in
multiple lobes (and even in the same lobe) of patients
undergoing SLB.22,29,30 Most importantly, the presence of
UIP in any lobe from a patient with IIP is associated with
impaired survival.22,29 The diagnosis of idiopathic NSIP
requires a dynamic integrated approach with input from
clinicians, radiologists, and pathologists. The survival of
patients with idiopathic NSIP is very good; however, addi-
tional studies are required to define the proper approach to
treatment and long-term follow-up. If disease is well
advanced, the outcome appears to be no different between
UIP and NSIP. In this regard, Latsi et al.14 showed that if the
DLCO was <35% predicted, there was a similarity in survival
between these two populations. The role of SLB needs to be
considered critically in the context of functionally severe
disease, in with fibrosis appears to be established; in this
case biopsy evaluation provided no prognostically useful
information.
A high profusion of fibroblastic foci in UIP has been
associated with higher mortality in patients with IPF in
several reports.10,31e33 Until recently, fibroblastic foci were
considered to be discrete sites of lung injury or repair
(Fig. 1). However, on the basis of morphometric analysis
with three-dimensional reconstruction, fibroblastic foci
appear to be highly interconnected and may represent the
edge of a complex reticulum extending from the pleura into
the underlying parenchyma.34 However, a potential sources
of bias of these studies is that the current pathologic
criteria for diagnosis of UIP requires presence of
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fibrosis, as well as fibroblastic foci interspersed with areas
of completely normal lung. Biopsy specimens cannot
represent the extent of fibroblastic activity of the entire
lungs, as it is unclear what part of the lung is represented
by the biopsy. Thus, one cannot make prognostic implica-
tions based on biopsy samples. It seems that although SLB is
required for the diagnosis in atypical IPF cases, it cannot be
accurate for comparison of disease activity in different
patients due to heterogeneous nature of pathology.24,35
The value of HRCT in defining prognosis in IPF
When assessed by expert clinicians and radiologists, the
presence of typical clinical and HRCT features is sufficient
to allow a confident diagnosis of IPF in more than 50% of
suspected cases and may eliminate the need for SLB in
these patients.5,36,37 Thus, HRCT has become an integral
part of evaluation of patients with IIP.1,38
The characteristic HRCT findings of UIP include the
following: honeycombing, reticular opacities, ground-glass
attenuation, and both basal and peripheral predominance,
which is often associated with traction bronchiectasis and
architectural distortion.39e41 One of the key findings that
suggests the diagnosis of UIP on HRCT imaging is the pres-
ence of honeycomb cysts in a basilar sub-pleural distribu-
tion. Honeycomb changes appear on the HRCT scan as
variably-sized cystic spaces that share walls and
frequently stack upon one another in several layers (Fig. 2).
The presence of centrilobular emphysema can sometimes
make the diagnosis of honeycombing more difficult.38
It has been reported that initial HRCT findings have
prognostic significance in IPF, in that the patients with an
atypical pattern for IPF on HRCT had better prognosis than
those with typical HRCT pattern for IPF.42e44 One of the
most striking findings of a recent study is the variable HRCT
appearance of UIP despite very rigid histopathologic
criteria. Interestingly, only approximately one-third ofFigure 2 HRCT demonstrates bilateral honeycomb cysts. The
honeycombing is more extensive on the left side. A sub-pleural
predominance of the honeycomb cysts is particularly evident
on the right side.HRCTs showed definite IPF and approximately one-third
suggested an alternative diagnosis, such as NSIP, or were
unclassifiable45,46 (Fig. 3). Another study found a high
prevalence of histopathologic UIP in patients with an HRCT
appearance of indeterminate or NSIP.42
HRCT appearance and quantification of features,
particularly fibrosis, can be useful to stratify the risk of
subsequent mortality for patients with IPF/UIP. The extent
and pattern of fibrosis on HRCT scans carry prognostic
implications. For example, a multivariate analysis of a large
multicenter trial47 suggested that a higher extent of fibrosis
on HRCT scans was an independent predictor of mortality.
When using a visual scoring method, IPF exhibits a progres-
sive deterioration both in the extent of disease seen on
HRCT scans and in lung function impairment over time,
although the changes were subtle and evolved gradually. In
clinical practice, the HRCT scan visual score of disease
extent can be used in association with function tests to
monitor IPF evolution, and to evaluate prognosis and
therapy.9 On the other hand, when compared to physiologic
measures, longitudinal changes in HRCT scans during short-
term follow-up are less predictive of survival during inter-
mediate follow-up.12 Use of computerized methods to
quantify the amount of fibrosis and ground glass infil-
trate48,49 may be more sensitive to serial changes in HRCT
findings but require additional study. Additional studies are
required to better define the role of serial HRCT in the
follow-up of patients with UIP.
Pulmonary function test (PFT)s: implication for
survival
Most published studies in predicting survival time in
patients with IPF have looked at the predictive value of
baseline variables.10,11,50e54 A number of baseline predic-
tors of survival in IPF have been proposed; however, there
has been little consistency across studies. A retrospective
study analyzed mortality according to baseline functional
parameters among 168 IPF patients in the placebo arm of
a randomized phase III clinical trial. In this analysis, a lowFigure 3 HRCT shows ground-glass opacities, mild reticula-
tion, and marked traction bronchiectasis in a case of NSIP. It
should be noted that there is considerable overlap between the
HRCT findings seen in NSIP and those present in other inter-
stitial pneumonias.
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of death, but the % predicted FVC did not.55 In another
studies, patients with DLCO of less than 35% predicted had
a bed prognosis, linked to the severity of pulmonary
disfunction (and the severity of pulmonary disease) and not
to the histopathologic pattern/diagnosis (UIP or NSIP).14,56
On the basis of these results one group has proposed
a simple stratification system characterizing patients with
IPF and patients with NSIP as having advanced disease if the
baseline DLCO is less than 39% predicted and limited if the
DLCO is greater than 40% predicted.57,58
In practice, clinicians generally refine prognostic
impressions (and sometimes revisit histologic diagnoses) in
individual cases according to longitudinal behavior. Disease
progression has historically been monitored through clinical
status and lung function tests, although with the advent of
HRCT, there is potential for further refinement, with the
serial imaging findings providing data relating to disease
progression.59 PFT, as a non-invasive quantitative measure-
ment, is the cornerstone of current practice in the assess-
ment of the disease severity and progression. However,
pulmonary function evaluation at presentation is disap-
pointingly imprecise, prognostically53,60; the prognostic
value of pulmonary function trends over time may prove
more useful.13,14 Furthermore, lung function trends are
especially useful when they show unequivocal change
(decline or clear-cut stability). However, a large subset of
patients exhibitsmarginal deterioration, withmay represent
either true decline or the “noise” of measurement. Longi-
tudinal changes in FVC or DLCO have been found to have
important prognostic value. A decrease in FVC of at least 10%
or DLCO of at least 15% over 6 or 12months is associated with
decreased survival.12e14,56 FVC is a better predictor than
DLCO, which is less reproducible. Although change in FVC is
a good surrogate for subsequent mortality, it is imperfect as
some patients die without a 10% decline in FVC, whereas
others can live for prolonged periods even after a 10% decline
in FVC.7,8,55 Although a lower rate of decrease in lung func-
tion does not necessarily translate into longer survival,
changes in FVC have been shown to be predictive of survival
in at least one large trial.55 Because serial resting PFTs are
the only outcomemeasures shown to be linked tomortality in
IPF, they are increasingly preferred as primary endpoints,
with FVC chosen in recent IPF studies.61e64 However,
a number of issues remain to be clarified. The optimal time
interval for repetition of PFT in treatment trials has not been
established as, in the above studies of pulmonary function
trends against mortality, no shorter time interval than 6
months was used to define pulmonary function trends. In
most studies, PFTswere repeated every 3e4months. It is not
clear whether PFT trends should be analysed as continuous
data (with sub-group comparisons made using t-testing or
non-parametric ranked analyses). This approach is usual in
treatment studies but an alternative approach is to examine
the prevalence of ‘significant’ decline (categorical analysis).
Continuous analysis presupposes that disease progression is
likely to be broadly unimodal, whereas categorical analysis,
which may be more suited to bimodal patterns of progres-
sion, lends itself to ‘time to decline’ analyses, such as
progression-free survival.65
Clinical (dyspnea scale), radiographic features (chest
radiograph), and weighted pulmonary function parametersincluding exercise testing have been combined to generate
a clinical/radiographic/physiologic score (CRP).66 The
correlation of CRP score and histologic severity is good,
although clinical validation and use of this staging tech-
nique is limited.66,67 This CRP scoring system was recom-
mended as a quantitative tool for the serial assessment of
clinical impairment in patients with IPF.66,67 A new CRP
score was generated to determine whether the risk of
death caused by respiratory failure could be predicted
based on clinical, radiologic, and physiologic parameters
obtained during initial evaluation.50 This model is an
accurate predictor of survival time in IPF but requires
radiographic analysis and exercise physiologic measure-
ments not readily available to many physicians: this may
limit its practical utility as a predictor of survival time.50Exercise tests: implication for survival
Patients with IPF have impaired ventilatory and cardiovas-
cular responses to exercise68 due to multiple abnormalities,
including low tidal volume, a failure to decrease ventilator
dead space, a rapid, shallow breathing pattern, impaired
gas exchange due to interstitial fibrosis, pulmonary hyper-
tension, ventilation/perfusion mismatching and low mixed
venous O2. Gas exchange worsens with exercise in IPF.17,69
Several studies have examined this feature using either
cardiopulmonary exercise tests (CPET) or the 6-minute-
walk test (6MWT). A decrease in PaO2 during CPET in
patients with IPF contributes up to 10.5% of the total CRP
score50 used to estimate prognosis in IPF. Desaturation
during CPET has been shown to predict mortality in some69
but not all52,60 studies. It is now known that in IPF,
maximal exercise data and especially the degree of oxygen
desaturation are very poorly reproducible, as judged by
major inter-test variation at an interval of 1week,70 and this
makes the definition of significant change highly problem-
atic. VO2max is an integrated measure of cardiovascular,
respiratory, and neuromuscular function.71 In prior studies
of patients with interstitial lung disease, VO2max
correlated poorly with measures of lung volume, suggesting
that it more accurately reflects derangements in hemody-
namics as well as ventilation during exercise.68 VO2max
examined as a continuous variable does not predict
mortality in IPF. However, baseline threshold VO2max of
8.3 ml/kg/min predicts mortality patients with IPF. This
threshold is a robust predictor of survival when compared
with desaturation less than 88% during a 6MWT and resting
PaO2. Demographic and pulmonary function data can be
used to estimate whether VO2max is above or below the
8.3 ml/kg/min threshold.72 However, not all studies show
that CPET measurements of gas exchange predict
survival.52,60 Several authors have examined the prognostic
value of the 6MWT or other walk tests in IPF. The 6MWT has
emerged as an important addition to prognostic evaluation,
with significant oxygen desaturation identifying a subgroup
of patients with a much higher mortality.73,74 Desaturation
during 6MWT,73,74 distance walked,75,76 and progressive
impairment in longitudinal 6MWTs77 have been found to
predict mortality in IPF. In a study of patients listed for
transplantation, a walk distance of less than 207 m was
associated with a fourfold increase in mortality and was
S6 A. Caminati, S. Hararimore prognostically accurate than FVC levels.75 In our
recent study,76 we demonstrated that distance walked
during 6MWT was significantly correlated with pulmonary
functional parameters (DLCO, VC, FVC). We also demon-
strated that distance walked in 6 min was independently
related to mortality in IPF and patients walking less than
212 m had a significantly lower survival rate than those
walking farther as assessed by Kaplan-Meier survival curves;
212 m in our study group identified a cut-off distance with
a bad prognosis and the use of a change in meters walked as
a continuous variable confirms the ability of distance
walked to predict a less favorable outcome. Thus, our data
confirm recent observation that distance walked during 6-
MWT may serve as prognostic indicator in IPF, which may
complement other prognostic markers.
The simplicity of the 6MWT and its probable ability to
assess complex physiologic interactions and predict prog-
nosis make the 6MWT an important tool for the manage-
ment of patients with IPF. One criticism of the 6MWT is that
it is a patient-driven, symptom and effort-limited test. This
may explain the controversy in the literature about
whether distance walked or desaturation is a better
predictor of mortality.
Specific clinical situations affecting prognosis
Acute exacerbations of IPF
A growing body of evidence suggests that IPF evolves with
different clinical phenotypes. IPF usually presents insidi-
ously with symptoms and signs of progressive respiratory
insufficiency that slowly progress over a period of months to
years. The natural history is invariably one of gradual and
progressive deterioration, with median length of survival
from the time of diagnosis ranging from 2 to 3 years.1,17,21
Although chronic in nature, an accelerated phase may
occur at any stage in the history of the disease without
identifiable cause, leading to death in a period of a few
weeks to a few months.8,78 These episodes are called
‘‘acute exacerbations’’ of IPF. Acute exacerbations of IPF
are increasingly recognized as common and highly morbid
clinical events.7,79,80 A 2-year frequency of acute exacer-
bations of approximately 10% has now been reported in
a cohort of 147 patients with IPF,81 underlining the need for
a reappraisal of the risk factors and management of this
often-lethal disorder. The following criteria have generally
been included in most studies9,82 for the definition of acute
exacerbation: (1) acute worsening of dyspnea within 1
month of presentation; (2) new pulmonary infiltrates seen
on CXRs or CT scans; (3) deterioration in pulmonary func-
tion measurements or gas exchange; and (4) absence of an
identifiable cause, including infections or cardiovascular
disease. The histologic findings from lung biopsy specimens
show variable aspects; the typical UIP pattern is associated
with signs of acute lesions, such as diffuse alveolar damage
(DAD) with or without hyaline membranes, numerous
fibroblastic foci, organizing pneumonia (OP), and hemor-
rhage with capillaritis.82e84 Churg and colleagues85
described that three microscopic patterns of acute lung
injury were seen in acute exacerbation of UIPdDAD, OP,
and a pattern of numerous very large fibroblastic focisuperimposed on underlying fibrosisdand that patients
with OP or extensive fibroblastic foci as the acute pattern
seem to do better than those with DAD. Martinez and
colleagues retrospectively analyzed the course of 168
patients with IPF.7 Mortality rates may be as high as 60 to
70% over 3 to 6 months.86
Acute exacerbation may repeat in some patients with
UIP. In addition, acute exacerbation may be the presenting
manifestation in some patients with UIP.82,87 An acceler-
ated variant of UIP in two previously healthy patients with
no known interstitial lung disease is reported.88 The
accelerated variant of UIP is associated with evidence of
peripheral ground-glass opacities and consolidation. Sub-
pleural reticulation or honeycombing is not been demon-
strable on the initial CT examination. Traction bronchiec-
tasis and cysts were not seen on CT in the two patients until
37 days after presentation. Pathological findings in these
two cases were consistent with a diagnosis of UIP.88
Accelerating variant of UIP had no a chronic course of
follow-up and no reticular or honeycomb pattern consistent
with IPF on the initial chest HRCT scans, but might have
subclinical UIP. Accelerating variant of UIP may be an acute
exacerbation in patients with subclinical UIP. Acute exac-
erbations of IPF have become increasingly important as
a target for therapy. For example, one clinical study79
comparing pirfenidone with placebo was prematurely
terminated by the Data Safety Monitoring Board when
a higher number of acute exacerbations was noted in the
placebo group (placebo group, 5 of 35 patients; pirfenidone
group, 0 of 35 patients). Kubo et al.,80 in studying the utility
of anticoagulation as a possible treatment for IPF, noted
that the major cause of clinical deterioration was acute
exacerbation. In a study of cyclosporine- treated patients
vs those treated without cyclosporine, Homma et al.89
suggested a better prognosis with regard to the acute
exacerbation of IPF in the cyclosporine-treated group.
These studies indicate that acute exacerbations may be
a potential therapeutic target in IPF. Confirmation of these
potential therapeutic effects in larger, longer term studies
are necessary.Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a common accom-
paniment of IPF, may contribute substantially to morbidity
and mortality in IPF90,91 and has a significant impact on
outcomes.90,92 Apossible explanation for thedevelopmentof
PAH is that of progressive fibrosis resulting in destruction of
the pulmonary vasculature. If the PAH of IPF is due to
progressive fibrosis, then one might expect to see a rela-
tionship between measures of fibrosis and the prevalence
and severity of PAH. Any authors hypothesized that
progressive fibrosis is mostly responsible for the PAH of IPF
and assessed the relationship between physiologic measures
of fibrosis andPAH.Contrary to initial hypothesis, the authors
failed to demonstrate any such correlations. Pathologic
vascular findings in IPF consist of changes in the arteries,
arterioles, and venules, and destruction of the capillary bed,
which are traditionally attributed to hypoxia and fibrosis,
respectively. Advential thickening around the pulmonary
vessels occurs due to an increase of fibroblasts,
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muscle cell hypertrophy and proliferation and collagen and
elastin accumulation occur in the media of the small
muscular pulmonary arteries, and distal pulmonary arteri-
oles become muscularized. These changes are consistent
with those seen in other hypoxia-related lung diseases.93 PAH
is often observed in the clinical course of IPF patients with
advanced disease. Lettieri et al.90 reported a prevalence of
31.6% among IPF patients who underwent the evaluation
while waiting for lung transplantation. In this study, there
was a significant difference in survival between those with
and without PAH (p< 0.001). For example, the 1-year
mortality rates were 28% and 5.5%, respectively, for those
with and without PAH. Despite the documented associations
between PAH and the risk of death, the presence of PAH did
not adequately discriminate between patients with high and
low short termmortality, providing sensitivity and specificity
estimates of <80%.75,90,94 In estimations of PAP by Nadrous
et al.92 using the ultrasonic cardiography method, systolic
PAPwas>50 mmHg in 30.7% of patients. In patientswith IPF,
especially those with more advanced disease, evaluating for
the presence of PAH may be useful in determining prognosis
andmayhavea role inmonitoring thedisease course, triaging
for lung transplantation, and deciding on potential thera-
pies. Surrogate markers, such as a reduced DLCO, the need
for supplemental oxygen, or a poor performance on the
6MWT, should raise suspicion for the presence of PAH and the
need for confirmatory right heart catheterization.90Other predictors under investigation
An area of debate is the utility of bronchoalveolar lavage
(BAL) for diagnosis and/or prognostication in IPF. Although
the pattern of cells recovered with BAL may narrow the
differential diagnosis of interstitial pneumonias, its role in
IPF remains controversial.17 The differential cell count
from samples of BAL fluid has been used with limited
success to monitor the progression of IPF and to predict the
disease prognosis. The presence of BAL lymphocytosis was
shown to shift diagnostic probabilities from IPF to hyper-
sensitivity pneumonitis or sarcoidosis. In patients with IPF,
as then diagnosed, BAL lymphocytosis denoted a better
outcome from treatment.95 Current noninvasive diagnostic
criteria for IPF include the absence of a significant BAL
lymphocytosis in the setting of clinical and HRCT findings
typical of IPF.1,17 Although clinical-radiologic-pathologic
evaluation is considered to be the “gold standard” for the
diagnosis of IIPs, there are certain limitations for the
performance of a SLB in elderly patients with IPF, including
severely impaired pulmonary function, the risk of acute
exacerbation, and potential significant comorbidities. In
clinical practice, less than 30% of patients are estimated to
have had SLBs.96 In addition, previous studies have
demonstrated interlobar variability and/or interobserver
variation, suggesting that the pathologic evaluation alone
may result in an incorrect diagnosis.22,29,42 A previous study
have demonstrated that granulocytosis or neutrophilia in
BAL is an important diagnostic and prognostic factor in
IPF.97 In this large, well-defined IPF population with long-
term follow-up it was showed that baseline BAL fluid
neutrophil percentage was a strong predictor of 1-yearmortality.97 To date, studies53,98,99 evaluating the associa-
tion of BAL fluid cellular constituents and mortality have
yielded conflicting results about the prognostic value
of BAL.
Surfactant protein (SP) A and SP-D are members of the
collectin family. Secreted primarily by alveolar epithelial
type II pneumocytes, plasma SP-A and SP-D levels appear to
increase early after breakdown in the alveolar epithe-
lium.100,101 SP-A has been shown102,103 to be present in
abnormal amounts in the BAL fluid of patients with IPF. A
recent study examined the association of serum SP-A and
SP-D levels with survival in a relatively large and well-
characterized cohort of patients with biopsy-proven IPF
through long-term and comprehensive follow-up.104 This
study demonstrated that serum SP-A levels obtained at the
time of initial diagnosis among patients with IPF is inde-
pendently and strongly associated with death or lung
transplant within 1 year after presentation.104 The authors
believe that the most likely explanation for the association
between serum SP-A levels and mortality in patients with
IPF is that serum SP-A levels may be a more sensitive
indicator of the extent of lung involvement than any of the
conventional functional parameters, such as DLCO or FVC.
Some advantages of using this measurement as a prognostic
indicator include the ease in obtaining blood samples
compared to other more invasive or more expensive
measures, the reproducibility and limited interobserver
variability of the test, and the relative strength of its
association with mortality compared to other conventional
measures. Increased serum SP-A concentrations may iden-
tify a subset of patients with more “active” disease that
increases the risk of death in the following year and was not
predicted by other baseline, noninvasive clinical predic-
tors, such as lung function test results.104Conclusions
The non-invasive diagnosis of IIP is sometime uncertain but
histologic evaluation is an imperfect gold-standard. In some
cases, the biopsy specimen may not be representative of
the entire lung. In other cases, there may be differences in
interpretation of the histologic findings. In particular, the
histologic distinction between fibrotic NSIP and UIP is
difficult and is subject to substantial interobserver varia-
tion. A previous study showed that the kappa coefficient of
agreement between two experienced pathologists for dis-
tinguishing UIP from fibrotic NSIP was only 0.26.19 Pulmo-
nary pathologists are still working to reach consensus on
how to draw a distinction between fibrotic NSIP and UIP. In
borderline cases, HRCT images may help by showing
features more typical of one or the other disease.
IPF remains a devastating parenchymal lung disease,
prognosis is poor and death generally occurring as result of
slowly progressive respiratory failure.1,21 More recently, it
has been recognized17,21,53 that some patients without end-
stage fibrosis have an acute exacerbation of IPF involving
a rapid progression of disease, rendering the clinical course
of an individual patient unpredictable.105 Individual disease
course is variable; periods of relative stability are common
but acute exacerbation may cause abrupt worsening of
symptoms. While clinical predictors are useful in describing
S8 A. Caminati, S. Hararithe natural history of IPF, disease progression in individuals
remains difficult to predict. Several predictors of survival
have been identified that assist in prognosis but nearly half
of the deaths in a large prospective randomized trial
occurred prior to evidence of disease progression.61 Staging
of disease is controversial. Baseline parameters that are
predictive of clinical outcome include dyspnea, DLCO,
desaturation on the 6MWT, pulmonary arterial pressure,
HRCT pattern (key feature is honeycomb), and pathologic
diagnosis of UIP. Dynamic prognostic indicators include
dyspnea, FVC, and DLCO. Short-term trends in DLCO or FVC
are the most accurate determinants of survival in fibrotic
IIP, with FVC trends sometimes easier to interpret, because
of lower variability. Serial change in FVC, defined as
percentage change from baseline, is the most widely
accepted primary end-point for therapeutic studies in
pulmonary fibrosis, based upon prognostic evaluation in IPF.
It is important to remember that no predictor of survival
can ever reliably predict an individual patient’s prognosis.
Due to the great variability in the natural history of the
disease, close monitoring of the patients may be necessary
to evaluate the individual course of each patient.
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